Probucol

DB01599

small molecule approved investigational

Deskripsi

A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).

Struktur Molekul 2D

Berat 516.842
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Ranges from 12 hours to more than 500 hours, the longest half-life probably being in adipose tissue.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Absorption from the gastrointestinal tract is limited and variable (about 7%).

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with food. Food increases bioavailability.

Interaksi Obat

368 Data
Ivabradine Ivabradine may increase the QTc-prolonging activities of Probucol.
Dofetilide The risk or severity of QTc prolongation can be increased when Probucol is combined with Dofetilide.
Citalopram The risk or severity of QTc prolongation can be increased when Probucol is combined with Citalopram.
Anagrelide The risk or severity of QTc prolongation can be increased when Probucol is combined with Anagrelide.
Disopyramide The risk or severity of QTc prolongation can be increased when Probucol is combined with Disopyramide.
Clemastine The risk or severity of QTc prolongation can be increased when Probucol is combined with Clemastine.
Ibutilide The risk or severity of QTc prolongation can be increased when Probucol is combined with Ibutilide.
Valproic acid The risk or severity of QTc prolongation can be increased when Probucol is combined with Valproic acid.
Terfenadine The risk or severity of QTc prolongation can be increased when Probucol is combined with Terfenadine.
Grepafloxacin The risk or severity of QTc prolongation can be increased when Probucol is combined with Grepafloxacin.
Quinine The risk or severity of QTc prolongation can be increased when Probucol is combined with Quinine.
Sotalol The risk or severity of QTc prolongation can be increased when Probucol is combined with Sotalol.
Erlotinib The risk or severity of QTc prolongation can be increased when Probucol is combined with Erlotinib.
Toremifene The risk or severity of QTc prolongation can be increased when Probucol is combined with Toremifene.
Cisapride The risk or severity of QTc prolongation can be increased when Probucol is combined with Cisapride.
Imatinib The risk or severity of QTc prolongation can be increased when Probucol is combined with Imatinib.
Astemizole The risk or severity of QTc prolongation can be increased when Probucol is combined with Astemizole.
Thioridazine The risk or severity of QTc prolongation can be increased when Probucol is combined with Thioridazine.
Trovafloxacin The risk or severity of QTc prolongation can be increased when Probucol is combined with Trovafloxacin.
Mifepristone The risk or severity of QTc prolongation can be increased when Probucol is combined with Mifepristone.
Cocaine The risk or severity of QTc prolongation can be increased when Probucol is combined with Cocaine.
Quinidine The risk or severity of QTc prolongation can be increased when Probucol is combined with Quinidine.
Procainamide The risk or severity of QTc prolongation can be increased when Probucol is combined with Procainamide.
Pimozide The risk or severity of QTc prolongation can be increased when Probucol is combined with Pimozide.
Amiodarone The risk or severity of QTc prolongation can be increased when Probucol is combined with Amiodarone.
Arsenic trioxide The risk or severity of QTc prolongation can be increased when Probucol is combined with Arsenic trioxide.
Escitalopram The risk or severity of QTc prolongation can be increased when Probucol is combined with Escitalopram.
Domperidone The risk or severity of QTc prolongation can be increased when Probucol is combined with Domperidone.
Sparfloxacin The risk or severity of QTc prolongation can be increased when Probucol is combined with Sparfloxacin.
Halofantrine The risk or severity of QTc prolongation can be increased when Probucol is combined with Halofantrine.
Bepridil The risk or severity of QTc prolongation can be increased when Probucol is combined with Bepridil.
Paliperidone The risk or severity of QTc prolongation can be increased when Probucol is combined with Paliperidone.
Lithium cation The risk or severity of QTc prolongation can be increased when Probucol is combined with Lithium cation.
Temafloxacin The risk or severity of QTc prolongation can be increased when Probucol is combined with Temafloxacin.
Zuclopenthixol The risk or severity of QTc prolongation can be increased when Probucol is combined with Zuclopenthixol.
Tetrabenazine The risk or severity of QTc prolongation can be increased when Probucol is combined with Tetrabenazine.
Dronedarone The risk or severity of QTc prolongation can be increased when Probucol is combined with Dronedarone.
Nilotinib The risk or severity of QTc prolongation can be increased when Probucol is combined with Nilotinib.
Iloperidone The risk or severity of QTc prolongation can be increased when Probucol is combined with Iloperidone.
Vandetanib The risk or severity of QTc prolongation can be increased when Probucol is combined with Vandetanib.
Romidepsin The risk or severity of QTc prolongation can be increased when Probucol is combined with Romidepsin.
Asenapine The risk or severity of QTc prolongation can be increased when Probucol is combined with Asenapine.
Artemether The risk or severity of QTc prolongation can be increased when Probucol is combined with Artemether.
Lumefantrine The risk or severity of QTc prolongation can be increased when Probucol is combined with Lumefantrine.
Vemurafenib The risk or severity of QTc prolongation can be increased when Probucol is combined with Vemurafenib.
Eliglustat The risk or severity of QTc prolongation can be increased when Probucol is combined with Eliglustat.
Ribociclib The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Probucol.
Glasdegib The risk or severity of QTc prolongation can be increased when Probucol is combined with Glasdegib.
Deutetrabenazine The risk or severity of QTc prolongation can be increased when Probucol is combined with Deutetrabenazine.
Macimorelin The risk or severity of QTc prolongation can be increased when Probucol is combined with Macimorelin.
Terodiline The risk or severity of QTc prolongation can be increased when Probucol is combined with Terodiline.
Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Probucol.
Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Probucol.
Erythromycin The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Probucol.
Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Probucol.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Probucol.
Ranolazine The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Probucol.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Probucol.
Amitriptyline The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Probucol.
Methadone The risk or severity of QTc prolongation can be increased when Methadone is combined with Probucol.
Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Probucol.
Clozapine The risk or severity of QTc prolongation can be increased when Probucol is combined with Clozapine.
Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Probucol.
Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Probucol.
Promazine The risk or severity of QTc prolongation can be increased when Promazine is combined with Probucol.
Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Probucol.
Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Probucol.
Imipramine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Probucol.
Chlorpromazine The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Probucol.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Probucol.
Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Probucol.
Fluorouracil The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Probucol.
Perflutren The risk or severity of QTc prolongation can be increased when Perflutren is combined with Probucol.
Cinnarizine The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Probucol.
Atropine The risk or severity of QTc prolongation can be increased when Atropine is combined with Probucol.
Chloroquine The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Probucol.
Efavirenz The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Probucol.
Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Probucol.
Pentamidine The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Probucol.
Gadobenic acid The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Probucol.
Carbinoxamine The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Probucol.
Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Probucol.
Roxithromycin The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Probucol.
Nalidixic acid The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Probucol.
Cinoxacin The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Probucol.
Loperamide The risk or severity of QTc prolongation can be increased when Loperamide is combined with Probucol.
Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Probucol.
Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Probucol.
Levosimendan The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Probucol.
Mesoridazine The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Probucol.
Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Probucol.
Telithromycin The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Probucol.
Lomefloxacin The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Probucol.
Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Probucol.
Primaquine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Probucol.
Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Probucol.
Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Probucol.
Nifedipine The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Probucol.
Levofloxacin The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Probucol.
Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Probucol.

Target Protein

Phospholipid-transporting ATPase ABCA1 ABCA1
Liver carboxylesterase 1 CES1

Referensi & Sumber

Synthesis reference: Claudio Giordano, Giuseppe Barreca, "Process for preparing an intermediate useful in the syntheis of probucol." U.S. Patent US5157156, issued July, 1988.

Contoh Produk & Brand

Produk: 1 • International brands: 5
Produk
  • Lorelco
    Tablet • 250 mg • Oral • Canada • Approved
International Brands
  • Lesterol
  • Lurselle
  • Serterol
  • Sinlestal
  • Superlipid

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul